Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074676857> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2074676857 endingPage "19574" @default.
- W2074676857 startingPage "19574" @default.
- W2074676857 abstract "Etravirine has become an alternative in HIV/HCV coinfected patients because of safety and lack of interactions with anti-HCV drugs. The aim of this study was to establish the risk of liver toxicity in HIV/HCV coinfected patients receiving etravirine in the clinical setting, according to the degree of liver fibrosis and different accompanying drugs.Cohort study of 211 patients initiating etravirine as part of their antiretroviral regimen. HCV coinfection was defined as a positive RNA-HCV, whereas baseline liver fibrosis was assessed by transient elastography at baseline. Hepatotoxicity was defined as an increased AST/ALT, 5-fold higher over upper, normal limits for patients with normal baseline values, or 3.5-fold if altered at baseline.HCV coinfection was observed in 145 patients (69%) with a longer time of HIV infection and time on HAART than mono-infected patients, and a lower nadir (182 vs 227 cells/mL; p=0.02) and baseline CD4+ count (446 vs 552 cells/mL; p=0.02). Etravirine was used with two nucleoside analogues in 62%, with boosted darunavir in 17%, with raltegravir in 10%, and with darunavir plus raltegravir or maraviroc in 10% of patients without differences according to HCV serostatus. Transient elastography in 117 patients performed at etravirine initiation (median, 33 days) showed fibrosis 1 and fibrosis 4 in 37% and 24% of cases, and median stiffness value was 8.25 kPa (3.5-69). During an accumulated follow-up of 449.3 patient-years (median, 611 days), only one coinfected patient with fibrosis 4 (stiffness value, 50.1 kPa), receiving a rescue regimen including darunavir/r plus maraviroc plus two nucleoside analogues, developed a grade 3-4 of liver toxicity (0.5%). There were no other episodes of liver toxicity, as defined, and only 6 (3%) and 9 patients (4%) had a grade 1 and 2 of toxicity, respectively, in most cases related to HCV coinfection (6 and 6 cases). Moreover, HCV coinfection or advanced fibrosis was not associated to a higher risk of etravirine discontinuation (26% vs 21%; p=0.27, log-rank test) or virologic failure (9% vs 11%, p=0.56). CD4+ cell count increase was lower in HCV patients (+23 vs +86 at 6 month; p=0.02).Etravirine is safe in HIV/HCV coinfected patients, even in presence of moderate and advanced liver fibrosis and as part of different antiretroviral regimens." @default.
- W2074676857 created "2016-06-24" @default.
- W2074676857 creator A5027335368 @default.
- W2074676857 creator A5042565417 @default.
- W2074676857 creator A5048723768 @default.
- W2074676857 creator A5050955873 @default.
- W2074676857 creator A5056870679 @default.
- W2074676857 creator A5064873706 @default.
- W2074676857 creator A5074947927 @default.
- W2074676857 creator A5083110219 @default.
- W2074676857 date "2014-11-01" @default.
- W2074676857 modified "2023-10-18" @default.
- W2074676857 title "Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis" @default.
- W2074676857 doi "https://doi.org/10.7448/ias.17.4.19574" @default.
- W2074676857 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4224832" @default.
- W2074676857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25394081" @default.
- W2074676857 hasPublicationYear "2014" @default.
- W2074676857 type Work @default.
- W2074676857 sameAs 2074676857 @default.
- W2074676857 citedByCount "4" @default.
- W2074676857 countsByYear W20746768572016 @default.
- W2074676857 countsByYear W20746768572017 @default.
- W2074676857 crossrefType "journal-article" @default.
- W2074676857 hasAuthorship W2074676857A5027335368 @default.
- W2074676857 hasAuthorship W2074676857A5042565417 @default.
- W2074676857 hasAuthorship W2074676857A5048723768 @default.
- W2074676857 hasAuthorship W2074676857A5050955873 @default.
- W2074676857 hasAuthorship W2074676857A5056870679 @default.
- W2074676857 hasAuthorship W2074676857A5064873706 @default.
- W2074676857 hasAuthorship W2074676857A5074947927 @default.
- W2074676857 hasAuthorship W2074676857A5083110219 @default.
- W2074676857 hasBestOaLocation W20746768571 @default.
- W2074676857 hasConcept C126322002 @default.
- W2074676857 hasConcept C142462285 @default.
- W2074676857 hasConcept C203014093 @default.
- W2074676857 hasConcept C2776455275 @default.
- W2074676857 hasConcept C2777813720 @default.
- W2074676857 hasConcept C2778899366 @default.
- W2074676857 hasConcept C2779182219 @default.
- W2074676857 hasConcept C2780345285 @default.
- W2074676857 hasConcept C2780404665 @default.
- W2074676857 hasConcept C2780559512 @default.
- W2074676857 hasConcept C2780826214 @default.
- W2074676857 hasConcept C2781413609 @default.
- W2074676857 hasConcept C2993143319 @default.
- W2074676857 hasConcept C2994217296 @default.
- W2074676857 hasConcept C3013748606 @default.
- W2074676857 hasConcept C71924100 @default.
- W2074676857 hasConcept C72563966 @default.
- W2074676857 hasConcept C90924648 @default.
- W2074676857 hasConceptScore W2074676857C126322002 @default.
- W2074676857 hasConceptScore W2074676857C142462285 @default.
- W2074676857 hasConceptScore W2074676857C203014093 @default.
- W2074676857 hasConceptScore W2074676857C2776455275 @default.
- W2074676857 hasConceptScore W2074676857C2777813720 @default.
- W2074676857 hasConceptScore W2074676857C2778899366 @default.
- W2074676857 hasConceptScore W2074676857C2779182219 @default.
- W2074676857 hasConceptScore W2074676857C2780345285 @default.
- W2074676857 hasConceptScore W2074676857C2780404665 @default.
- W2074676857 hasConceptScore W2074676857C2780559512 @default.
- W2074676857 hasConceptScore W2074676857C2780826214 @default.
- W2074676857 hasConceptScore W2074676857C2781413609 @default.
- W2074676857 hasConceptScore W2074676857C2993143319 @default.
- W2074676857 hasConceptScore W2074676857C2994217296 @default.
- W2074676857 hasConceptScore W2074676857C3013748606 @default.
- W2074676857 hasConceptScore W2074676857C71924100 @default.
- W2074676857 hasConceptScore W2074676857C72563966 @default.
- W2074676857 hasConceptScore W2074676857C90924648 @default.
- W2074676857 hasLocation W20746768571 @default.
- W2074676857 hasLocation W20746768572 @default.
- W2074676857 hasLocation W20746768573 @default.
- W2074676857 hasLocation W20746768574 @default.
- W2074676857 hasOpenAccess W2074676857 @default.
- W2074676857 hasPrimaryLocation W20746768571 @default.
- W2074676857 hasRelatedWork W1972271159 @default.
- W2074676857 hasRelatedWork W1978760152 @default.
- W2074676857 hasRelatedWork W2060755150 @default.
- W2074676857 hasRelatedWork W2092018069 @default.
- W2074676857 hasRelatedWork W2108511174 @default.
- W2074676857 hasRelatedWork W2311765786 @default.
- W2074676857 hasRelatedWork W2415094934 @default.
- W2074676857 hasRelatedWork W2509806891 @default.
- W2074676857 hasRelatedWork W2752149978 @default.
- W2074676857 hasRelatedWork W4282970917 @default.
- W2074676857 hasVolume "17" @default.
- W2074676857 isParatext "false" @default.
- W2074676857 isRetracted "false" @default.
- W2074676857 magId "2074676857" @default.
- W2074676857 workType "article" @default.